Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
VVOS 
Vivos Therapeutics Inc (VVOS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: VVOS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.5
1 Year Target Price $5.5
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -14.95% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 18.61M USD | Price to earnings Ratio - | 1Y Target Price 5.5 |
Price to earnings Ratio - | 1Y Target Price 5.5 | ||
Volume (30-day avg) 2 | Beta 6.85 | 52 Weeks Range 1.98 - 7.95 | Updated Date 12/15/2025 |
52 Weeks Range 1.98 - 7.95 | Updated Date 12/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.77 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-19 | When - | Estimate -0.48 | Actual -0.49 |
Profitability
Profit Margin -98.76% | Operating Margin (TTM) -69.79% |
Management Effectiveness
Return on Assets (TTM) -49.76% | Return on Equity (TTM) -335.45% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 28016379 | Price to Sales(TTM) 1.07 |
Enterprise Value 28016379 | Price to Sales(TTM) 1.07 | ||
Enterprise Value to Revenue 1.62 | Enterprise Value to EBITDA -0.21 | Shares Outstanding 8988106 | Shares Floating 6917426 |
Shares Outstanding 8988106 | Shares Floating 6917426 | ||
Percent Insiders 24.66 | Percent Institutions 11.96 |
About Vivos Therapeutics Inc
Exchange NASDAQ | Headquaters Littleton, CO, United States | ||
IPO Launch date 2020-12-11 | Co-Founder, Chairman of the Board & CEO Mr. R. Kirk Huntsman | ||
Sector Healthcare | Industry Medical Devices | Full time employees 262 | Website https://www.vivos.com |
Full time employees 262 | Website https://www.vivos.com | ||
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.